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ABSTRACT 
Correlative  imaging  has  long  been  used  in  clinical  practice  and  particularly  for  the  interpretation  of  nuclear 
medicine  studies  wherein  detailed  anatomical  information  is  often  lacking.  Previously,  side-by-side  comparison  or 
software  co-registration  techniques  were  applied  but  suffered  from  technical  limitations  related  to  the  differing 
geometries of the imaging equipment, differences in the positioning of patients and displacement of mobile structures 
between studies. The development of the first hybrid PET and CT device struck a chord with the medical imaging 
community that is still ringing loudly throughout the world. So successful has been the concept of PET-CT that none of 
the major medical imaging manufacturers now offers stand-alone PET scanners. Following close behind this success, 
SPECT-CT devices have recently been adopted by the nuclear medicine community, already compelled by the benefits 
of hybrid imaging through their experience with PET-CT. Recent reports of adaptation of PET detectors to operate 
within the strong magnetic field of MRI scanners have generated further enthusiasm. Prototype PET-MRI devices are 
now  in  development.  The  complementary  anatomical,  functional  and  molecular  information  provided  by  these 
techniques  can  now  be  presented  in  an  intuitive  and  aesthetically-pleasing  format.  This  has  made  end-users  more 
comfortable  with  the  results  of  functional  imaging  techniques  than  when  the  same  information  is  presented 
independently.  Despite  the  primacy  of  anatomical  imaging  for  locoregional  disease  definition,  the  molecular 
characterisation available from PET and SPECT offers unique complementary information for cancer evaluation. A new 
era of cancer imaging, when hybrid imaging will be the primary diagnostic tool, is approaching. © 2007 Biomedical 
Imaging and Intervention Journal. All rights reserved. 
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INTRODUCTION 
At medical schools throughout the world, doctors in 
training are taught the basic sciences of anatomy, biology, 
physiology, biochemistry, and so forth. However, when 
it comes to diagnostic imaging, there is a heavy reliance 
placed  on  tutelage  regarding  anatomically-based 
techniques while molecular and functional techniques are 
often given scant attention. Most clinicians are therefore 
very comfortable with using CT, X-rays, ultrasound and 
MRI  because  the  output  is  readily  understood, 
particularly if the images are accompanied by judiciously 
placed arrows demonstrating the abnormalities. Nuclear 
medicine  techniques,  apart  from  bone  scanning,  which 
resembles  sufficiently  the  mind’s  eye  perception  of  a 
skeleton  to  pass  as  an  anatomical  representation,  have 
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often failed to capture the imagination of the clinician. 
There is a feeling that functional imaging is somehow 
less  valid  than  radiological  techniques  because  of  the 
lack  of  fine  spatial  resolution.  The  term  “unclear 
medicine”  is  a  common  derogator  used  by  clinicians 
when discussing the work of nuclear medicine imaging 
specialists. Perhaps this partly reflects the complexity of 
the  principles  that  underpin  these  techniques  and  that 
often do not lend themselves to “gestalt” interpretation. 
Time-activity  curves,  deconvolutional  analysis  and 
compartmental modelling are all based on mathematics 
and  are  generally  held  to  be  beyond  common 
understanding. 
Nevertheless,  the  general  public  deals  with 
functional information on a daily basis and can integrate 
it into decision-making processes if it is presented in an 
intuitive format. An obvious example appears in weather 
reports  on  television  or  computer  screens  where  serial 
radar images of rainfall are displayed over a map of a 
geographical  region  with  appropriate  labelling  of 
landmarks.  Different  colours  are  used  to  display  the 
intensity  of  precipitation  and  a  cinematic  function  is 
utilised to demonstrate the movement of a storm system 
across the land. The end-user can easily decide whether 
to take an umbrella on their walk, or to bring in their 
drying clothes from the washing-line on the basis of such 
information  without  understanding  the  complexities  of 
radar,  global  positioning  systems,  satellites  or 
meteorology. Hybrid imaging provides a similar intuitive 
integration of information from functional and structural 
imaging  techniques  without  requiring  a  detailed 
understanding  of  the  technologies  needed  to  produce 
them.  
THE HISTORY OF HYBRID IMAGING 
Nuclear medicine actually started as a non-imaging 
specialty  with  probes  used  to  measure  radioactivity  in 
restricted regions of the body, such as the thyroid gland. 
The first practical form of nuclear medicine imaging was 
that performed on rectilinear scanners [1]. These devices 
had  a  very  small  scintillation  detector  that  moved 
methodically over the body to produce, usually with a 
1:1 scaling, dots on paper or, later, film proportional to 
the number of radioactive events recorded in a particular 
unit  of  time.  Because  the  resulting  images  were  “life-
size”,  they  could  be  easily  overlaid  on  plain  X-rays, 
which  were  also  acquired  without  magnification.  This 
fusion  of  X-rays  and  rectilinear  scans  was  used,  for 
example, to diagnose subphrenic collections prior to the 
availability  of  CT  scanning  (Figure  1).  Clearly, 
“anatamometabolic” imaging is not a new concept. 
The  development  of  the  gamma  camera  by  Hal 
Anger increased the capacity for imaging larger regions 
of  the  body  simultaneously  but  limited  the  ability  to 
perform  direct  correlations  with  anatomical  images 
because  the  film  or  computer-generated  images  were 
usually  minified.  However,  with  the  development  and 
increasing  clinical  application  of  tomographic  imaging 
techniques  such  as  CT  and  SPECT  in  the  1980s  and 
1990s,  interest  in  image  fusion  increased.  Being 
computer-generated and therefore of an intrinsic digital 
format,  the  images  from  these  tomographic  techniques 
were  amenable  to  software  manipulations  including 
translation,  rotation,  rescaling  and,  potentially,  to 
deformation. Because of the lack of deformation in brain 
structures,  software  solutions  for  image  co-registration 
were most successful for neurological applications [2, 3].  
However,  even  early  in  the  development  of  SPECT, 
fusion  of  anatomical  and  functional  information  was 
performed to assess the distribution of radioligands that 
provided  limited  anatomical  information  in  their  own 
right.  Examples  include  radiolabeled  monoclonal 
antibodies [4, 5]. 
Relatively early in the development of clinical PET 
in oncology the advantages of correlating structural and 
metabolic information were also recognised [6]. PET co-
registration with both CT and MRI found direct clinical 
application in the guidance of neurosurgery [7]. It was 
also  found  to  improve  the  accuracy  of  staging  lymph 
node  involvement  in  patients  with  non-small  cell  lung 
cancer  (NSCLC)  [8]  and  was  used  in  radiotherapy 
planning [9]. 
From the concept of image registration and fusion, it 
was a relatively short intellectual leap of faith to develop 
hybrid scanners. GE Medical Systems first commercially 
 
Figure 1  A fusion of a rectilinear scan using I-131 rose Bengal 
with  a  chest  X-ray  outlining  the  position  of  the 
diaphragm  was  used to diagnose  subphrenic abscess 
before the availability of CT scanning and ultrasound. 
This  represented  one  of  the  first  examples  of 
“anatamometabolic” imaging. 
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released a SPECT camera with an X-ray source capable 
of  providing  low-dose  CT  images.  This  device,  which 
went by the trade name “Hawkeye”, immediately found 
application in oncology [10, 11]. Although this iteration 
of SPECT-CT was available slightly earlier before PET-
CT in a commercial sense, the CT on the Hawkeye was 
of suboptimal diagnostic quality and added significantly 
to the total acquisition time of a routine SPECT study. 
The  development  of  combined  PET-CT  systems 
integrating a diagnostic CT by Townsend and co-workers 
has revolutionised hybrid imaging [12]. Early versions of 
these  hybrid  devices  incorporated  partial-ring  PET 
scanners but further development has led to state-of-the-
art  PET  and  multi-detector  CT  (MDCT)  now  being 
integrated into current devices [13]. The first combined 
PET-CT to be available commercially was the Discovery 
LS scanner (GE Medical Systems, Milwaukee, WI). This 
device pragmatically involved simply bolting what were 
then current generation PET and MDCT devices together 
and using a newly-designed patient bed (Figure 2).  
RECENT DEVELOPMENTS IN HYBRID IMAGING 
Subsequent developments have seen the advent of 
PET-CT  designed  as  an  integrated  hardware  and 
software platform. Such has been the success of hybrid 
PET-CT scanners that none of the major manufacturers 
currently  offers  stand-alone  PET  scanners  for 
commercial sale. Recent advances include incorporating 
64-slice  MDCT,  new  detector  technologies  and 
development  of  time-of-flight  scanners  [14,  15].  The 
rapid  take-up  of  PET-CT  in  clinical  practice  has 
generated significant economies of scale to be realised in 
the manufacture of systems and led to a significant fall in 
the  cost  of  these  systems  or  availability  of  more 
technologically-advanced systems at comparable prices. 
It  has  also  stimulated  reinvestment  in  instrumentation 
research and development, which had stalled for many 
years as PET languished as a primarily research tool with 
a  low  installed  base.  Accordingly,  significant 
improvements in performance with respect to resolution 
and scan acquisition times are expected in the near future. 
Following  the  success  of  PET-CT  scanners  with 
integrated  diagnostic  MDCT,  Philips  and  Siemens 
(Figure  3)  both  subsequently  introduced  SPECT-CT 
scanners  that  also  included  a  diagnostic  MDCT.  The 
superior diagnostic quality of the CT on these scanners, 
particularly for soft tissues in the abdomen, and the much 
shorter CT acquisition times offer significant advantages 
over the GE Hawkeye system. However, these systems 
are more expensive and involve higher radiation doses 
[16]. Hence the choice of system is highly dependent on 
the range of applications for which the scanner will be 
used. 
Despite the success and popularity of PET-CT and, 
more  recently,  of  SPECT-CT,  there  are  some 
shortcomings  in  the  use  of  CT  as  a  complementary 
anatomical imaging modality. Firstly, CT adds radiation 
dose to the overall examination, particularly if used in a 
full  diagnostic  role  [17].  Secondly,  CT  provides 
relatively poor soft tissue contrast in the absence of oral 
and  intravenous  iodinated  contrast,  particularly  if  low-
dose  acquisition  protocols  are  utilised  to  minimise 
incremental  radiation  exposure.  These  two  theoretical 
limitations do not apply to MRI, which does not involve 
ionising radiation and provides soft tissue imaging with 
high spatial resolution and superior contrast compared to 
CT. MRI can also provide more advanced ‘functional’ 
techniques  such  as  diffusion  and  perfusion  imaging  as 
well as spectroscopy, which may be complementary to 
 
Figure 2  The Discovery LS (GE Medical Systems, Milwaukee, 
WI)  was  the  first  commercial  PET-CT  scanner  to 
become  available.  This  scanner  at  these  authors’ 
institution  was  installed  in  2001  and  has  now 
performed over 12,000 scans. Implementation of this 
scanner involved end-by-end installation of a 4-slice 
Lightspeed plus CT with the GE Advance NXi PET 
scanner  with  a  new  patient  bed.  The  CT  and  PET 
components  operated  on  independent  computer 
platform. 
 
 
Figure 3  Modern hybrid SPECT-CT scanners incorporate multi-
detector  CT.  This  is  the  Siemens  Symbia  6  system 
installed in these authors’ facility. 
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functional  information  obtained  by  PET.  Furthermore, 
the  high  sensitivity  of  PET  may  also  complement  the 
poor signal strength inherent in current functional MRI 
imaging. The combination of PET and MRI into a single 
scanner  may therefore prove to be the ultimate  hybrid 
imaging  modality,  combining  the  metabolic  and 
molecular  information  of  PET  with  the  excellent 
anatomical detail of MRI, while offering new potential 
applications with respect to functional MRI techniques 
[18].  
There have been several recent publications on the 
value of fused or co-registered PET-MRI images in pre-
clinical and clinical practice (19-22). There are, however, 
a number of technical problems to be overcome before a 
hybrid  PET-MRI  scanner  can  become  a  reality.  Both 
MRI and PET have the potential to affect each other’s 
performance  in  their  current  form.  One  of  the  main 
problems is that the photomultiplier tube, a fundamental 
component of current PET detectors, will not function in 
a ‘magnet’ as the high magnetic field causes electrons to 
deviate from their original trajectory, resulting in loss of 
gain.  A  small  prototype  PET-MRI  scanner  has  been 
developed  using  long  optical  fibres  to  transport  light 
from the detector to photomultiplier tubes situated in a 
low field region [23].  
A  small  5.4  cm  diameter  MRI-compatible  PET 
scanner  operating  within  the  bore  of  a  9.4T  MRI 
spectroscopy system and a 4.7T small bore animal MRI 
imaging system have been developed successfully. There 
is however significant light loss in the long optical fibres, 
leading to poor energy and time resolution. This design 
is likely to be impractical for a large number of detectors 
since the large volume of optical fibres required would 
probably  significantly  limit  the  axial  field  of  view.  A 
more  promising  alternative  is  the  use  of  avalanche 
photodiode (APD) technology, which is a compact and 
reliable  silicon-based  device.  APDs  have  successfully 
replaced photomultiplier tubes in a high resolution PET 
system, and can function in high magnetic fields of up to 
9.4T  without  any  performance  degradation.  A 
performance test of an APD-based LSO PET detector in 
a 7 T animal research MRI scanner yielded encouraging 
results  [24].  There  was  only  slight  degradation  of  the 
PET  detector  energy  spectra  caused  by  magnetic 
gradients or RF pulses. 
Current  efforts  in  the  development  of  PET-MRI 
scanner have focused on small animal systems, because 
the  technical  requirements  for  such  systems  are  less 
demanding  and  applications  are  readily  apparent  [25]. 
However, one commercial vendor, Siemens, has already 
showcased  the  first  human  PET-MRI  system  at  the 
Radiological Society of North America Meeting in 2006 
and  preliminary  imaging  studies  have  been  reported 
using  a  prototype  PET-MRI[26].  The  Siemens  device 
uses  a  MR-compatible  lutetium-oxalate  (LSO)  crystal-
based avalanche photodiode detector. The field of view 
in a combined mode with a PET head insert is estimated 
to be about 20cm axially and 24cm radially. This means 
that  this  system  is  primarily  suitable  for  brain,  and 
possibly  other  small  parts,  imaging.  There  are  many 
potentially  useful  PET-MRI  applications  in  the  brain, 
including  neurodegenerative  disorders,  epilepsy  and 
tumours.  Obviously,  at  this  time,  the  majority  of  data 
supporting  such  instrumentation  comes  from  cross-
platform  correlative  studies.  For  example,  a  PET-MRI 
correlative  study  reported  positive  relations  between 
hippocampal  atrophy  and  ipsilateral  association  cortex 
hypometabolism  in  Alzheimer’s  disease  [27].  Digitally 
performed  PET-MRI  coregistration  was  also  found  to 
increase childhood CNS tumour characterisation in 90% 
of the cases and can be used to obtain a more specific 
diagnosis with regard to tumour grading [20]. There was 
also a report comparing the uptake of C
11-choline PET 
tracer to the choline peak on proton MR spectroscopy 
(MRS) in the assessment of brain tumours, suggesting 
that they were both helpful in the differential diagnosis 
of  cerebral  lymphoma,  glioma  and  non-tumour  lesions 
[28].  
MRS imaging displays the relative concentrations of 
chemical metabolites within a small volume of interest or 
voxel.  In  vivo  proton  spectroscopy  is  most  widely 
available and is used to look at biochemical alterations in 
cancers  and  in  characterisation  of  the  ‘chemistry’  of 
target lesions. It provides biochemical information that 
may  be  complementary  to  the  metabolic  information 
obtained  from  PET,  but  unlike  PET,  does  not  expose 
patients to ionising radiation. In clinical oncology, MRS 
was initially developed for assessment of human brain 
tumours  but  has  since  been  extended  to  evaluation  of 
prostate and breast cancers. The roles of proton MRS in 
oncology include refinement of preoperative differential 
diagnosis  data,  which  can  be  used  to  guide  surgical 
biopsy  procedures,  and  detection  and  monitoring  of 
treatment response [29]. 
Traditionally,  MRI  scanning  has  been  limited  to 
assessment  of  limited  body  regions  due  to  prolonged 
imaging  time  and  limited  availability.  The  new 
development of Total Imaging Matrix (TIM) technology 
allows  fast,  high-resolution  whole-body  MRI  imaging 
without the need for patient or surface coil repositioning. 
The TIM used in the Siemens MAGNETOM AVANTO 
scanner combines 32 independent receiver channels with 
76  array  coil  elements  that  can  be  connected 
simultaneously  [30].  With  advancing  technology  and 
increasing demand for high quality fast imaging, whole 
body  human  PET-MRI  scanner  might  be  available  in 
clinical practice in the not too distant future. 
HYBRID IMAGING: EVOLUTION OR REVOLUTION? 
It is easy to contend that the development of hybrid 
imaging  was  merely  an  evolution  of  principles  of 
correlative  imaging  developed  over  the  past  50  years.  
However,  there  is  no  doubt  that  this  technology  has 
revolutionised  the  way  that  clinicians  think  about 
imaging.  The  fused  image  has  become  the  preferred 
visualisation  tool  of  the  end-user  of  imaging 
investigations, the clinician. Although clearly better than 
contrast  agents,  the  superimposition  of  radiotracer 
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signals on a set of CT or MRI images with which the 
clinician feels comfortable, has increased confidence in 
the  veracity  of  the  molecular  information  and  its 
pathological or physiological basis.  
In  the  case  of  PET-CT,  besides  the  aesthetic 
advantages,  it  has  become  clear  that  accurately  co-
registered images increase diagnostic accuracy compared 
to independent or side-by-side reading of PET and CT 
data, but more substantially increase the confidence with 
which  abnormalities  are  localised.  The  literature 
evaluating  PET-CT  is  rapidly  expanding  but  the  vast 
majority of preliminary and recent studies have attested 
to incremental diagnostic value compared to PET or CT 
in  a  wide  range  of  malignancies  (31-44).  Better 
localisation  of  abnormalities  can  have  significant 
management  implications,  particularly  in  areas  of 
complex  anatomy  [45].  Using  the  CT  to  provide  an 
attenuation map with which to correct emission data has 
been  another  major  advantage  of  hybrid  PET-CT 
scanning.  Previously  various  radioactive  sources 
including Ge-68 and Cs-137 [46] were used to determine 
the loss of energy of detected annihilation photons due to 
tissue attenuation as they passed through the body. Since 
PET image reconstruction relies currently on detection of 
coincident  detection  of  2  photons,  many  photon  pairs 
must  pass  through  the  entire  diameter  of  the  body, 
creating  significant  degradation  in  sensitivity  for  deep 
structures  and  restricting  quantification  of  regional 
radioactivity.  Acquisition  of  transmission  scans  using 
radioactive sources was often a time-consuming process, 
sometimes occupying as much as one third of the total 
acquisition time in order to achieve adequate statistical 
quality to provide an accurate map of tissue attenuation. 
Although innovative techniques including simultaneous 
transmission  and  emission  scanning  [47]  reduced  this 
impost, the ability to acquire a whole-body attenuation 
map  in  less  than  1  minute  using  a  MDCT  has 
dramatically  reduced  this  component  of  a  PET  scan. 
Despite the higher instrumentation costs, the more rapid 
scan  acquisition  protocols  available  on  current  hybrid 
 
Figure 4  A  dedicated  single-bed  position  study  acquired  after  whole  body  acquisition  allows  for  active 
intervention and optimisation of CT acquisition protocols. This is particularly helpful in regions of 
complex anatomy like the neck and upper abdomen. These authors use this capacity for evaluation of 
gastric cancers, performing studies without and with gastric distension. The images on the left represent 
those with the stomach collapsed whereas those on the right are following gastric distension with an oral 
fluid load and buscopan to minimise gastric motility. 
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PET-CT scanners allows significantly higher throughput, 
allowing economies of scale to maintain or reduce the 
unit cost of individual scans. 
When the authors’ PET facility began operation in 
1996, a PET scan extending from the base of the brain to 
the  mid-thigh  required  an  emission  scan  of  close  to  1 
hour and a transmission scan of around 20 minutes in 
duration. Since  most studies were processed  with both 
attenuation  correction  and  iterative  reconstruction,  the 
time taken to produce an image set for analysis was often 
an  hour  or  more.  With  such  time  constraints,  the 
procedure was limited to 6-8 patients per day. Today, the 
same axial extent of the body can be scanned in less than 
30 minutes. Some scanners are capable of less than 10-
minute  whole-body  scan  acquisition  times.  As  a 
consequence, we are able to perform 15 or more scans 
per scanner per day. This leads to more efficient use of 
radiotracers  with  rapid  radioactive  decay,  greater 
amortisation of equipment and other fixed costs, such as 
maintenance.  It  also  allows  more  productive  use  of 
technologist, nursing, secretarial and medical staff. 
Modern computing platforms also allow almost real-
time reconstruction of images. The advantages of this to 
patient comfort and convenience are obvious. This has 
been reflected in a lower likelihood of patient movement 
during  the  scan  and  ability  to  review  scans  while  the 
patient is still on the bed, so that additional images can 
be acquired if required. This facility is routinely used in 
evaluating carcinoma of the stomach. A whole-body scan 
is  first  acquired  with  the  stomach  empty.  This  allows 
separation of the gastric  wall from adjacent structures, 
including  peri-gastric  lymph  nodes.  If  there  is  no 
evidence of systemic metastasis on this scan, the patient 
is  administered  buscopan  as  a  smooth  muscle  relaxant 
and given 500 ml of water to drink in order to distend the 
stomach. This leads to stretching of the gastric smooth 
muscle, attenuating signal from it through partial volume 
effects,  while  more  clearly  demarking  the  site  of  the 
primary  lesion,  which  being  less  compliant  than  the 
normal stomach, maintains its signal despite distension 
(Figure 4).  
The  greater  statistical  quality  of  CT  transmission 
maps  has  also  been  advantageous  in  improving  the 
quality  of  PET  scans.  However,  the  fact  that  the 
attenuation  characteristics  of  X-rays  and  annihilation 
photons  for  varying  tissues  are  significantly  different 
means  that  correction  factors  are  required  to  translate 
from a CT-attenuation map to an appropriate 511 keV 
map. This can lead to some discordance in quantitative 
analysis  of  tissue  tracer  activity  [48,  49].  Soft  tissue 
attenuation  is  less  of  a  problem  for  SPECT 
reconstruction, since acquisition data in each projection 
are dominated by photons arising closest to the detector 
and thereby passing through the shortest distance of the 
body. Development of SPECT-CT systems has allowed 
more robust attenuation correction to be performed. This 
is  most  helpful  in  the  abdomen,  where  the  density  of 
abdominal organs significantly reduces measured activity 
from  deep  abdominal  structures,  particularly  in  obese 
patients.  However,  because  attenuation  correction  was 
not  a  routine  part  of  standard  nuclear  medicine  and 
SPECT was often seen as an adjunct to planar imaging 
due  to  the  incremental  acquisition  times  required, 
SPECT-CT  has  not  resulted  in  increased  throughput 
capacity.  Accordingly,  SPECT-CT  is  more  expensive 
than standard nuclear medicine procedures because the 
equipment is more expensive than a conventional gamma 
camera,  and  to  optimally  leverage  the  diagnostic 
advantages  of  this  technology  it  needs  to  be  used 
primarily as a tomographic device rather than for high 
throughput planar scanning. The relatively low usage of 
the  expensive  CT  component  of  the  scanner  could  be 
viewed as wasteful. However, it is believed that flexible 
imaging protocols that maximise the benefits of hybrid 
SPECT-CT  can  be  developed.  These  include  having 
dedicated planar scanners for whole-body screening and 
to  acquire  spot  views.  These  would  then  feed  into  a 
SPECT-CT  scanner  for  dedicated  regional  imaging 
studies  to  better  define  diagnostic  questions  that  were 
inadequately resolved by planar imaging. 
In  a  hybrid  PET-MRI  system  for  whole  body 
imaging,  the  issue  of  attenuation  correction  for  PET 
using  MRI  images  will  need  to  be  resolved. 
Segmentation  and  remapping  algorithms  will  likely  be 
required.  
DISADVANTAGES OF HYBRID TECHNOLOGY 
Although the CT and PET or SPECT components of 
hybrid imaging studies are acquired contemporaneously, 
they are not acquired simultaneously. Accordingly, this 
allows  for  movement to occur between  the  two scans. 
The most common form of movement is that associated 
with normal respiration [50]. It was recognised early in 
the  development  of  PET  that  cardiac  and  respiratory 
movement  significantly  degraded  image  quality  and 
gating was identified as a solution to this problem [51]. 
Because of the rapid acquisition of CT images using a 
MDCT it is possible to acquire images during a single 
breath-hold or even during normal breathing, fixing the 
position of structures like the diaphragm, lungs, liver and 
spleen that move with respiration. The emission images 
take  minutes  to  acquire  at  each  bed  position  and 
therefore  respiratory  blurring  of  the  image  can  occur. 
During  normal tidal volume  breathing the lungs spend 
more of their time closer to an end-expiratory  volume 
than to an end-inspiratory volume and certainly not at the 
degree of expansion associated with a forced inspiration, 
which is the preferred state for diagnostic CT of the chest. 
Thus, comparison of the CT images with the integrated 
PET  emission  image  demonstrates  a  degree  of 
misregistration  at  the  level  of  the  diaphragm  although 
this infrequently causes major diagnostic problems [52]. 
The most common finding is that CT structures appear to 
be lower than the corresponding metabolic signal. This 
misregistration is also manifested in the assignment of 
the attenuation characteristics to structures at around the 
level of the diaphragm. By incorrectly assuming counts 
that have actually arisen within dense liver parenchyma 
6 RJ Hicks et al. Biomed Imaging Interv J 2007; 3(3):e49     
    This page number is not 
    for citation purposes 
 
 
Figure 5  Misregistration  of  artefacts  due  to  respiratory  motion  lead  to  crescent-shaped  areas  of  relative 
photopenia  at  the  level  of  the  diaphragm.  In  this  case  of  lung  cancer  previously  treated  with 
radiotherapy, a larger and more profound artefact is apparent in the left hemi-thorax (right panel), than 
on the right (left panel). presumably due to greater respiratory excursion of the untreated lung. 
 
 
 
 
Figure 6  The high tumour to background ratios obtained with agents such as Tc-99m antimony colloid, used for 
lymphoscintigraphy,  limit  the  anatomical  localisation  of  abnormalities  on  SPECT  alone.  Fusion  of 
SPECT and CT data redresses this limitation. The ability to demonstrate to the surgeon the precise 
location of the sentinel node means that the correct node is more likely to be sampled and that operative 
time and morbidity may be reduced by better surgical planning. 
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came from aerated lung based on the CT-attenuation map, 
these  counts  are  given  less  weighting  and  therefore 
appear as an area of relative photopenia on reconstructed 
images (Figure 5). Various manoeuvres have been tried 
to eliminate these misregistration artefacts. These have 
included  altering  breath-holding  to  mid-inspiration  or 
end-expiration during acquisition of the CT component. 
It has been found that any instruction regarding breathing 
tends to significantly alter breathing pattern and therefore 
the  authors  have  chosen  to  simply  acquire  the  CT 
without any instructions to the patient other than to lie 
still. For situations where extremely accurate registration 
of  anatomical  and  structural  information  is  required, 
respiratory gating of both the CT and PET components 
may be an option but it places time constraints on the 
study  and  requires  a  more  sophisticated  set-up. 
Nevertheless,  this  may  be  worthwhile,  particularly  for 
planning  treatment  of  basal  lung  cancers.  Techniques 
have been developed to allow what is termed 4d PET-CT 
[53]. 
Gross physical movements can also occur. Making 
the patient aware of the need to remain still, efforts to 
make them as comfortable as possible and to reduce total 
scan  time  are,  in  the  authors’  experience,  the  most 
efficacious  methods  of  reducing  patient  movement. 
Some  facilities,  however,  use  body  restraints  that 
minimise the capacity for patient movement. Even with 
physical  restraints,  patient  movements  can  occur  and 
give  rise  to  both  attenuation  artefacts  and  diagnostic 
difficulties related to misregistration of PET and CT data. 
Unlike  PET-CT,  where  PET  and  CT  imaging  are 
acquired sequentially, simultaneous acquisition of PET 
data and MRI images is possible in a hybrid PET-MRI 
scanner as the PET scanner operates within the bore of 
the  MRI  magnet.  This  provides  for  the  first  time 
simultaneous anatomical and functional imaging with not 
only potentially perfect fusion PET-MRI images but also 
the prospect of performing dynamic imaging to obtain 
valuable functional information. 
SHOULD HYBRID IMAGING BE AN ADJUNCT TO OR 
REPLACEMENT OF ANATOMICAL IMAGING? 
Because of the relatively high cost of PET and its 
restricted availability in many parts of the world, PET 
has  been  generally  reserved  for  cases  with  equivocal 
conventional imaging results. However, in the authors’ 
experience, the major impact of FDG PET is to prevent 
futile  procedures  in  patients  in  whom  PET  detects 
metastatic disease unrecognised by conventional staging 
techniques  irrespective  of  whether  there  was  any 
equivocation  on  these  tests.  Since  most  oncological 
therapies  are  selected  and  monitored  based  on  the 
presence and extent of apparent disease, more accurate 
definition of these parameters is important to appropriate 
treatment delivery. For example, in radiotherapy patients, 
for whom adequate coverage of gross tumour volume is 
vital  to  achieving  local  control  and  survival,  better 
definition  of  macroscopic  regional  nodal  disease  and 
exclusion  of  distant  metastases  would  be  expected  to 
improve  patient  outcomes  [54].  More  precise 
characterisation of the nature and location of focal FDG 
accumulations identified by PET-CT is likely to further 
improve diagnostic performance and thereby, treatment 
selection and planning. By avoiding unnecessary or futile 
surgery,  radiotherapy  or  chemotherapy  and  better 
assessing  the  response  to  these  treatments,  there  is 
substantial opportunity to not only improve patient care 
but also to reduce costs, despite the higher upfront cost 
of the imaging component of the management paradigm 
if PET-CT and other hybrid imaging tests were used as 
the primary diagnostic test. There is increasing evidence 
across a broad range of indications that hybrid PET-CT 
 
Figure 7  Accurate  attenuation  correction  can  aid  semi-
quantitative analysis of lesional uptake of therapeutic 
radionuclides like Lu-177 octreotate or its diagnostic 
pair In-11 octreotide. This can aid dosimetry planning 
for radionuclide therapy. 
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[55]  and  hybrid  SPECT-CT  (56-61)  are  usually  more 
accurate that either modality allow and not infrequently 
when  compared  to  side-by-side  comparison  of  each 
modality  acquired  separately.  The  huge  number  of 
studies  being  published  using  these  technologies  will 
continue to refine the clinical performance and role of 
hybrid  imaging  but  there  is  no  doubt  that  there  is  no 
turning  back.  The  future  of  cancer  imaging  lies  with 
hybrid imaging technologies. Because of the extremely 
high  contrast  associated  with  many  SPECT  tracers 
(Figure 6), the authors  find  that the addition of CT is 
even more valuable than it is to FDG PET wherein there 
is  already  substantial  vicarious  anatomical  information 
by  way  of  uptake  in  normal  tissues.  An  emerging 
application  of  SPECT-CT  will  be  the  development  of 
algorithms for radionuclide therapy dosimetry planning 
(Figure 7). 
Post-script  note:  Although  no  mention  of  optical 
imaging  is  made  above,  there  is  preliminary  work  on 
tomographic imaging devices based on this technology 
[62]. The primary author is of the opinion that optical 
imaging  will  have  increasing  clinical  application  and 
may  one  day  also  be  the  subject  of  clinical  hybrid 
imaging platforms.  
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